Pulmonary and Critical Care Fellowship Research

During the second and third year of fellowship fellows have an opportunity to pursue supervised research for an average of 12 months in total. During these months the fellows are not on core clinical rotations. The Program Director (PD), the associate PD for research and Division Chief usually begin discussions of research focus with fellows during their first year by hosting a “research open-house” to showcase all the divisional faculty and their ongoing/anticipated research projects. In addition, fellows are encouraged to initiate research questions on their own and to find an appropriate mentor to assist them in developing the project (sometimes even outside the division). After exploring what a fellow’s interests are, the faculty comprising the research advisory council (RAC) recommend specific mentors and projects. The fellow then meets with several possible research mentors and chooses accordingly.

Select fellows are offered a fourth year of fellowship (non-ACGME). This fellowship year has protected research time with a focus on developing skills needed to become a successfully funded independent researcher.

RAC also meets with all research fellows to monitor progress of their research projects and milestones. Additional opportunities through Masters in Clinical Research, Masters in Public Health, Quality Improvement & training grants are available. 

  • Studying factors associated with patient self-induced lung injury (P-SILI) during NIPPV using Mount Sinai Data Warehouse: Dr. Neha Goel
  • Predictive capacity of the ROX index in extubation using Mount Sinai Data Warehouse: Dr. Neha Goel
  • Using early warning signs by machine learning and AI in predicting ICU admission for sepsis: Dr. Pranai Tandon
  • Determination of biomarkers and gene expression profiling in early stage adenocarcinoma specimens of lung cancer: Dr. Charles A. Powell
  • Using SEER-Medicare databases to investigate outcomes in diverse populations with HIV, COPD, ILD, asthma and lung cancer: Dr. Juan Wisnivesky, Dr. Alex Federman and Dr. Keith Sigel
  • Investigation of lung injury and repair mechanisms using mouse models with staphylococcal infection: Dr. Jaime Hook
  • Sleep apnea and outcomes of atherosclerosis (leveraging state of the art vascular imaging and PET scans): Dr. Neomi Shah
  • Effect of household air pollution on infant lung health, an interventional study in Ghana with clean burning cook-stoves: Dr. Alison Lee
  • Determinants of asthma outcomes in inner city population in Baltimore (dietary factors, microbiome, indoor environmental pollution): Dr. Sonali Bose
  • Studying the complex interplay between OSA and diastolic heart failure: Dr. Thomas Tolbert
  • Studying the factors associated with OSA and its bidirectional interaction with systemic and local inflammation: Dr. Oren Cohen
  • Effect of OSA treatment with CPAP and atherosclerotic inflammation: Dr. Vaishnavi Kundel
  • Clinical trial: PreCISE: Adaptive platform study of 5 therapies for severe and exacerbation prone asthma: Dr. Linda Rogers, Dr. Sonali Bose, Dr. Monica Kraft, Dr. Elliott Eisenberg
  • Clinical trial: Improving Medication Adherence with Telehealth-care Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma (MATCH): Dr. Linda Rogers, Dr. Sonali Bose, Dr. Monica Kraft, Dr. Elliott Eisenberg
  • Clinical trial: HAPPI: A Study of women who are pregnant (1st or 2nd trimester) with a physician diagnosis of asthma to remotely evaluate their asthma control throughout pregnancy and assess indoor home air quality and dietary factors which may influence asthma control: Dr. Sonali Bose
  • Clinical trial: REGAIN-observational asthma registry study -collection of nasal brushings and blood and optional use of digital inhaler monitor focused on enrolling patients on stable biological therapy and patients about to start biological therapy: Dr. Linda Rogers
  • Clinical trial: RELIANCE (PCORI) for patients with COPD who have been hospitalized within the past year for a COPD exacerbation despite baseline COPD therapy randomized to open label Azithromycin vs Roflumilast in a pragmatic study: Dr. Linda Rogers, Dr. Kathryn Dubowski
  • Clinical trial: OBERON- studying the use of anti Tozorakimab anti IL33 Moab for severe COPD: Dr. Kathryn Dubowski
  • Clinical trials in IPF: Stop IPF: Patients with IPF who have failed anti fibrotic therapy or wish to enroll in trial as first strategy; Celgene trial:IPF patients on Pirfenidone as background therapy; ENDCOVI: Nintedanib in post covid lung disease with abnormal CT: Dr. Maria Padilla, Dr. Jennifer Ng and Dr. Jigna Zatakia
  • Clinical trial in bronchiectasis: MACr02  Epetraborolefor treatment refractory MAC:  Sarah Taimur and Dr. Christian Becker
  • Clinical trial: Phase II, multicenter study to investigate the efficacy, safety, and tolerability of CMK389 (IL-18 inhibitor) in patients with biopsy-proven chronic pulmonary sarcoidosis: Dr. Adam Morgenthau
  • OSA pathophysiology: leveraging sleep study data for sleep apnea physiology research, using a machine-learning/artificial-intelligence approach: Dr Ankit Parekh

Please take a look at a partial list of our fellows’ most recent publications and presentations.